RARA and acute myeloid leukemia: In terms of mechanism, compound 35 can upregulate RARA and downregulate MYC levels in MOLM13 cells, inhibiting the oncogenic FTO signaling pathway in AML cells, thereby demonstrating anti-leukemic activity.